Please assess the completion status of the following clinical trial:

Trial Title: Propaten Randomized Investigation on Cost-benefit and Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years of all ethnicities~* End-stage Renal Disease stage 4 (GFR 15-29 ml/min 1.73m2) or stage 5 (GFR \<15ml/min 1.73m2) per National Kidney Foundation guidelines~* Currently undergoing hemodialysis with a failure of previous access~* Expected to undergo hemodialysis within 6 months of presentation~Exclusion Criteria:~* Unable/refuse to abide with follow-up~* Known hypercoagulability syndrome or a bleeding disorder~* On a previous anticoagulant treatment~* Intraoperative decision in favor of fistula instead of graft~* Pregnant or breast-feeding women~* A documented history of heparin induced thrombocytopenia or allergy~* Active infections~* Evidence or suspicion of central vein stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PROPATEN (Type: EXPERIMENTAL): patients with heparin-bonded graft implantation
- Standard Graft (Type: ACTIVE_COMPARATOR): patients undergoing ePTFE hemodialysis graft implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).